Trade ReShape Lifesciences Inc. - RSLS CFD

Trading Conditions

• Spread: 0.05
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: N/A
• Open: 0.42
• 1-Year Change: 10.53%
• Day's Range: 0.38 - 0.55

ReShape Lifesciences Inc. Company profile

About ReShape Lifesciences Inc

ReShape Lifesciences Inc., formerly Obalon Therapeutics, Inc., is a weight-loss solutions company. The Company is focused on offering an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band and associated program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest System is an investigational minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. The ReShapeCare Virtual health coaching program is a virtual telehealth weight management program that supports lifestyle changes for all weight-loss patients, to help them keep the weight off over time. The Company's Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kilograms/ square meter.

Financial summary

BRIEF: For the nine months ended 30 September 2021, ReShape Lifesciences Inc revenues increased from $1.5M to $10.5M. Net loss increased from $11M to $26.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Stock-based Compensation in SGA increase from $790K to $8.1M (expense), Selling, general and administrative - B increase of 62% to $10.9M (expense).